TL;DR
In a phase IIb trial of adults with type 2 diabetes and overweight or obesity, the highest tested dose of eloralintide plus tirzepatide was associated with 23.3% average weight loss over 48 weeks, compared with 14.8% on tirzepatide alone. Adverse events were more common with the combination, and 27% of participants in that group stopped treatment because of them, versus 2.9% with tirzepatide alone. Eli Lilly plans to move the combination into phase III development by year-end.
A phase IIb trial in adults with type 2 diabetes found that the highest tested dose of investigational eloralintide plus tirzepatide was associated with 23.3% average body-weight loss over 48 weeks, compared with 14.8% among participants taking tirzepatide alone. The results, presented at the European Association for the Study of Diabetes meeting in Milan, came with a marked tolerability trade-off: 27% of the high-dose combination group discontinued because of adverse events, compared with 2.9% in the tirzepatide-only group.
The double-blind, parallel-group study randomized 367 adults with overweight or obesity and type 2 diabetes in the United States and Argentina. Participants were assigned across 10 groups, including placebo, eloralintide alone at different doses, tirzepatide alone, several combination-dose groups and a group that began tirzepatide before adding eloralintide at week 24. The drugs were given as two separate injections during the trial.
The 23.3% weight-loss result refers to the efficacy estimand for the highest-dose combination over 48 weeks; it should not be read as a result for every participant or every dose. A quarter of participants in that group lost at least 30% of their body weight, compared with 12% on tirzepatide alone, according to the trial results reported by MedPage Today. These are trial findings, not evidence that the combination is approved or available for routine treatment.
Blood-sugar measures were also reported. 96% in both the highest-dose combination and tirzepatide-only groups reached an HbA1c below 7%, while 77% of the combination group and 66% of the tirzepatide group reached below 5.7%. Treatment-emergent adverse events occurred in 84% of participants receiving the highest-dose combination and 71.4% of those on tirzepatide alone. One death occurred in a lowest-dose combination group and investigators judged it unrelated to the study drug, MedPage Today reported.
Weight Loss Came With More Withdrawals
The results suggest that adding an amylin-targeting drug to tirzepatide may increase weight loss for some adults with type 2 diabetes, a group that has historically tended to lose less weight on GLP-1-based medicines than people without diabetes. The size of the reported difference makes the combination a development to watch, but a phase IIb result is not proof of long-term benefit, and the comparison was limited to the study’s 48-week period and trial population.
The higher rate of stopping treatment is a central part of the finding, not a secondary detail. Nearly one in four participants in the highest-dose combination group discontinued because of adverse events, versus fewer than one in 30 on tirzepatide alone. For patients and clinicians, the balance between additional weight loss, glucose control and tolerability will matter when larger and longer studies assess whether the approach can be used in practice.
Three Hormone Pathways in One Regimen
Eloralintide is a selective amylin receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors. The combination is intended to act on three hormone pathways involved in appetite and blood-sugar regulation; Eli Lilly said these hormones are naturally released after eating and work through distinct receptors. The study tested the drugs together, but not as a single injection.
Trial presenter Liana Billings, MD, MMSc, of Endeavor Health in Evanston, Illinois, compared the combination’s weight-loss result with earlier experience using tirzepatide. She said the 23.3% figure exceeded the 20.9% reported for tirzepatide in people without diabetes, while noting that people with type 2 diabetes have historically lost less weight on GLP-1-based medicines. That comparison is between reported study results, rather than a head-to-head trial of the combination against tirzepatide in a non-diabetic population.
Eloralintide is also being studied as a single agent in phase III obesity trials. Eli Lilly plans to advance the combination into phase III by the end of the year, according to the source report. Further trial results will be needed before its benefits and risks can be judged across a broader population.
“These substances are released naturally by the body after eating, with each acting through its own distinct receptor to help regulate hunger and blood sugar.”
— Eli Lilly, in a statement cited in the report
Long-Term Benefit and Tolerability
The reported findings cover 48 weeks; whether weight loss continues after that point, and how durable the results are, is not established by the information available. The trial enrolled 367 people and divided them among 10 groups, so the reported percentages do not by themselves show how results would translate to broader patient populations or routine care.
The source report does not provide a full breakdown of adverse-event types, their severity, or why each participant stopped treatment. Nor does it establish whether the combination can sustain the observed blood-sugar measures over longer follow-up. The drugs were delivered as separate injections in this trial, and a planned single-shot formulation is not yet an established option. The combination remains investigational; regulatory status and eventual availability have not been reported.
Phase III Plans and Further Data
Eli Lilly plans to advance eloralintide plus tirzepatide into phase III development by the end of the year. Larger, later-stage studies will need to test whether the weight and HbA1c findings are reproducible and clarify the frequency, severity and causes of side effects and treatment discontinuation. The source report does not specify the phase III trial design, enrollment target or expected results date.
Researchers also expect to evaluate the combination in a single-injection formulation, according to Billings’ comments, though timing and development details were not provided. Until further evidence and any required regulatory review, the trial results should be understood as early clinical research rather than a change to current treatment options.
Key Questions
How much weight did participants lose on the combination?
In the trial’s efficacy estimand, participants receiving the highest tested dose of eloralintide plus tirzepatide lost 23.3% of body weight over 48 weeks, compared with 14.8% on tirzepatide alone. The result does not apply to every participant or dose.
Was blood-sugar control better with the combination?
96% in both groups reached an HbA1c below 7%. Below 5.7%, the figures were 77% with the highest-dose combination and 66% with tirzepatide alone. These are results from this trial, not a guarantee of an individual treatment outcome.
What safety concern was reported?
Treatment-emergent adverse events occurred in 84% of participants in the highest-dose combination group and 71.4% on tirzepatide alone. Discontinuation due to adverse events was 27% versus 2.9%, respectively. The source report did not detail the full event breakdown.
Is the combination available as a treatment?
No. Eloralintide plus tirzepatide is investigational and was studied in a phase IIb trial. Eli Lilly plans to move it into phase III development by the end of the year; no approval or availability was reported.
What are the two drugs designed to target?
Eloralintide targets the amylin receptor, while tirzepatide acts on GIP and GLP-1 receptors. The combination is designed to engage three hormone pathways involved in appetite and blood-sugar regulation.
Source: rss
